About this document
SGLT2 Inhibitors and Hyperkalemia Risks by Dara Mayang Sari is a document available to read on EtoBox.
This review discusses the impact of hyperkalemia on the use of therapies for diabetic kidney disease in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). It highlights that SGLT2 inhibitors can be safely used without increasing hyperkalemia risk, while nonsteroidal mineralocorticoid receptor antagonists require potassium monitoring. The combination of SGLT2 inhibitors and finerenone is suggested to provide additional cardiorenal benefits while managing potassium levels effectiv
- Author
- Dara Mayang Sari
- Language
- EN